Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one prior line of treatment met its primary endpoint. Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Overall survival (OS) data were immature at the time of interim analysis. The safety profile of the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting.